Top Markets
#1 Black Phoenix Black Phoenix +735.13%
#2 Beam Beam +32.89%
#3 SAFEcoin SAFEcoin +20.16%
#4 TENDIES TENDIES +17.65%
#5 Bless Bless +17.64%
#6 Biconomy Biconomy +16.89%
#7 EfficientFrontier EfficientFrontier +15.58%
#8 pipedog pipedog +15.03%
#9 THORChain THORChain +14.76%
#10 Versatize Coin Versatize Coin +12.50%
Coin of the day
Black Phoenix Black Phoenix
設定
言語
日本
通貨
USD
テーマ
Pharvaris N.V. Pharvaris N.V.

Pharvaris N.V.

PHVS
株式のランク #5575
Pharvaris N.V., a late-stage biopharmaceutical company, focuses on the... Pharvaris N.V., a late-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs covering angioedema and other bradykinin-mediated diseases. The company develops deucrictibant, a small molecule bradykinin B2-receptor antagonist to treat attacks due to bradykinin-mediated angioedema, including hereditary angioedema (HAE) and acquired angioedema due to C1-inhibitor deficiency (AAE-C1INH), which is in phase 3, as well as in phase 3 trials for treatment and prophylaxis of HAE attacks; and extended-release tablet and immediate-release capsule formulation of deucrictibant. Pharvaris N.V. was incorporated in 2015 and is headquartered in Zug, Switzerland.
株価
$36.98
最終同期: 2026-08-26
時価総額
$2.58B
変化（1日）
-0.67%
変化（1年）
55.51%
国
NL
取引 Pharvaris N.V. (PHVS)

カテゴリー

Healthcare
Pharvaris N.V.（PHVS）のP/B比率
2026 時点のP/B比率 TTM: 0
Pharvaris N.V. の最新の財務報告および株価によると、現在のP/B比率（TTM）は 0 です。2026 年末時点でのP/B比率は 0 でした。
Pharvaris N.V. の P/B 比率の履歴（2026 ～ 2026）
各年末時点のP/B比率
年 P/B比率 変化
提供された日付のデータは十分ではありません。
同業他社のP/B比率
企業 P/B比率 P/B比率の差 国
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 6.3419 -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 6.2413 -
NL
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 3.7087 -
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
 2.5054 -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH